In this randomized trial, the efficacy of propranolol in preventing rebleeding from severe portal hypertensive gastropathy in cirrhotics was compared with that of a control group not receiving propranolol. The 26 patients randomized to propranolol received the drug daily at a dose (20‐160 mg bid) that reduced resting heart rate by 25% or to 55 bpm, and were followed for a mean of 21 ± 11 (SD) months. The 28 nontreated controls received similar follow‐up for 18 ± 13 months. There were no significant clinical or biological differences between the two groups at entry to the trial. The actuarial percentages of patients free of rebleeding from portal hypertensive gastropathy were significantly higher in the propranolol‐treated patients than in the untreated controls at 12 months (65%vs. 38%; p < 0.05) and at 30 months of follow‐up (52%vs. 7%; p < 0.05). Actuarial survival was longer in the propranolol group than in controls, hut the difference was not significant. Propranolol‐treated patients had significantly fewer episodes of acute bleeding (p <0.05), but transfusion requirements were not statistically different (p= 0.08). Multivariate analysis showed that the absence of propranolol was the only predictive variable for re‐bleeding.
|Original language||English (US)|
|Number of pages||2|
|Journal||The American Journal of Gastroenterology|
|State||Published - Jul 1992|
ASJC Scopus subject areas